Do dimethyl fumarate and nicotinic acid elicit common, potentially HCA2‐mediated adverse reactions? A combined epidemiological‐experimental approach
British Journal of Clinical Pharmacology2021Vol. 87(10), pp. 3813–3824
Citations Over TimeTop 21% of 2021 papers
Diana Dubrall, René Pflock, Joanna Kosinska, Matthias Schmid, Markus Bleich, Nina Himmerkus, Stefan Offermanns, Markus Schwaninger, Bernhardt Sachs
Abstract
The gastrointestinal ADRs common to both substances may be mediated by HCA2 . Other ADRs not common to both substances are compound or indication-specific reactions and likely do not involve HCA2 .
Related Papers
- → Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate(2017)7 cited
- → Alopecia associated with dimethyl fumarate treatment for multiple sclerosis(2023)2 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → Preventing and managing dimethyl fumarate-related adverse effects in patients with multiple sclerosis may improve adherence(2018)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)